Simplifying Global Compliance
FDAnews Drug Daily Bulletin
XENCOR COMPLETES $6 MILLION BRIDGE FINANCING WITH NOVO NORDISK AND EXISTING INVESTORS
July 12, 2006
Xencor, a biotherapeutics company developing protein and antibody therapeutics,
today announced that it raised $6 million in a bridge financing from new investor
Novo Nordisk and existing investors including Zen Investments. Pursuant to the
bridge financing, Novo Nordisk has committed to invest an additional $6 million
in specified future financings.
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing